- Home
- NXGL vs NDRA Comparison
NXGL vs NDRA Comparison
Compare NXGL & NDRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NXGL | NDRA |
|---|---|---|
| Founded | 1997 | 2007 |
| Country | United States | United States |
| Employees | 19 | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9M | 5.5M |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | NXGL | NDRA |
|---|---|---|
| Price | $0.57 | $4.30 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $2.00 | ★ $30.00 |
| AVG Volume (30 Days) | ★ 105.0K | 14.7K |
| Earning Date | 05-11-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 84.32 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $50.77 | N/A |
| Revenue Next Year | $46.15 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.48 | $2.96 |
| 52 Week High | $2.89 | $11.91 |
Technical Indicators
Market Signals| Indicator | NXGL | NDRA |
|---|---|---|
| Relative Strength Index (RSI) | 46.97 | 37.56 |
| Support Level | $0.48 | $4.13 |
| Resistance Level | $0.64 | $4.83 |
| Average True Range (ATR) | 0.04 | 0.38 |
| MACD | 0.00 | -0.15 |
| Stochastic Oscillator | 43.31 | 4.53 |
Price Performance
Historical ComparisonAbout NXGL NexGel Inc
NexGel Inc manufactures high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company specializes in custom gels by capitalizing on proprietary manufacturing technologies. The gels and consumer products are manufactured using proprietary and non-proprietary mixing, coating and cross-linking technologies.
About NDRA ENDRA Life Sciences Inc.
ENDRA Life Sciences Inc is engaged in the development of Thermo Acoustic Enhanced UltraSound (TAEUS) to visualize tissue like MRI at the cost and at the point of patient care. TAEUS is designed to work in concert with around 400,000 cart-based ultrasound systems in use globally today. TAEUS is initially focused on the measurement of fat in the liver as a means to assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), chronic liver conditions that affect over one billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, the firm is exploring several other clinical applications of TAEUS, including visualization of tissue temperature during energy-based surgical procedures.